Stay updated on Daratumumab for AML/High-Risk MDS Clinical Trial
Sign up to get notified when there's something new on the Daratumumab for AML/High-Risk MDS Clinical Trial page.

Latest updates to the Daratumumab for AML/High-Risk MDS Clinical Trial page
- CheckyesterdayChange DetectedThe page now shows Revision: v3.6.5, replacing v3.6.4. This indicates a small update to the page's version metadata, with no changes to the study information.SummaryDifference0.1%

- Check8 days agoChange DetectedExpanded the study record with additional sections and documents, including the study protocol and statistical analysis plan PDF, sponsor/collaborator details, and updated dates and outcome measures. These additions provide deeper context about the trial's design, interventions, and results timeline.SummaryDifference47%

- Check15 days agoChange DetectedRevision: v3.6.4 added. A broad set of institutional names, document references, and related metadata were removed from the study record, indicating metadata cleanup rather than changes to the study design or eligibility.SummaryDifference17%

- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedRevision label changed from v3.6.2 to v3.6.3, indicating a minor version update to the page. This update is administrative and does not alter the page's substantive information.SummaryDifference0.1%

- Check44 days agoChange DetectedThe page's revision label changed from v3.6.0 to v3.6.2. This appears to be a minor metadata update with no substantive changes to the study information or page content.SummaryDifference0.1%

- Check58 days agoChange DetectedThe page now includes new user-help sections (No longer looking for participants; How to Read a Study Record; Common Questions; How to Join a Study) and a new revision tag (Revision: v3.6.0). The older label 'Intervention / Treatment' and the earlier revision tag (Revision: v3.5.5) were removed.SummaryDifference0.6%

Stay in the know with updates to Daratumumab for AML/High-Risk MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab for AML/High-Risk MDS Clinical Trial page.